Source: Annual Congress 2001 - Factors contributing to upper and lower airway responses
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Vaghi, G. De Bernardi, N. Grassi, S. Capato, G. Cicchitto, P. Sestini, M. Robuschi, S. Bianco (Milan, Siena, Italy). Tolerance of two cox2 - inhibitors, rofecoxib and celecoxib, in aspirin sensitive asthmatics. Eur Respir J 2001; 16: Suppl. 31, 2884

Member's Comments

No comment yet.

Related content which might interest you: No interaction of roflumilast, a new, orally active, selective PDE4 inhibitor, with inhaled salbutamol Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001 Roflumilast, a new, orally active, selective PDE4 inhibitor, does not interact with inhaled budesonide Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001 Comparison of roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, with beclomethasone dipropionate in asthma control Source: Eur Respir J 2002; 20: Suppl. 38, 304s Year: 2002 Tolerance to COX-2 inhibitors in patients intolerant to aspirin: challenge mandatory Source: Eur Respir J 2003; 22: Suppl. 45, 547s Year: 2003 Efficacy and safety of four doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i), in patients with moderate-to-severe COPD Source: International Congress 2019 – COPD clinical trials: new molecules and novel insights Year: 2019 Roflumilast, an oral, once-daily PDE4 inhibitor, improves lung function and reduces exacerbation rates in patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 21s Year: 2004 High oral absolute bioavailability of roflumilast, a new, orally active, once daily PDE4 inhibitor Source: Eur Respir J 2001; 18: Suppl. 33, 20s Year: 2001 Smoking has no effect on the pharmacokinetics of roflumilast, a new, orally active, selective PDE4 inhibitor Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001 First-dose bronchodilating effect of phosphodiesterase-4 (PDE-4) inhibition by cilomilast (Ariflo) with or without coadministration of salbutamol and/or ipratropium in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001 Safety, tolerability and pharmacokinetics of CHF 6001, a novel selective inhaled PDE4 inhibitor, in healthy volunteers Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016 Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, is effective in the treatment of asthma Source: Eur Respir J 2002; 20: Suppl. 38, 303s Year: 2002 Clinical and biochemical differences between patients with aspirin-induced asthma/rhinitis Source: Annual Congress 2005 - PG18 - Inter-relationships between upper and lower airway diseases Year: 2005 Safety, pharmacokinetics, and pharmacodynamics of TD-8236, an inhaled pan-JAK inhibitor, following single- and multiple-ascending doses in healthy volunteers and mild asthmatics Source: Virtual Congress 2021 – Clinical trials in airway diseases: novel treatments and new evidence Year: 2021 Roflumilast, a PDE4 inhibitor, improves lung function in patients with COPD treated with tiotropium Source: Annual Congress 2009 - Treatment of COPD Year: 2009 Effect of CYP3A4 inhibitors verapamil and itraconazole on the pharmacokinetics of AZD7986, an oral DPP1 inhibitor Source: International Congress 2017 – Asthma management Year: 2017 Roflumilast, a selective phosphodiesterase 4 inhibitor, shows efficacy and safety in the long-term treatment of asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 Bronchoprotective activity of sildenafil (Viagra) in asthmatics Source: Eur Respir J 2001; 18: Suppl. 33, 429s Year: 2001 Pharmacological agents used to treat asthma Source: ISSN=1025-448x, ISBN=1-904097-26-x, page=339 Year: 2003 Influence of food intake on the pharmacokinetics of roflumilast, a new, orally active, selective PDE4 inhibitor Source: Eur Respir J 2001; 18: Suppl. 33, 42s Year: 2001 Safety, tolerability and pharmacokinetics of a new inhaled once-daily phosphodiesterase (PDE) 4 inhibitor in healthy volunteers Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013